Search

Your search keyword '"Jacoby, Meagan A."' showing total 365 results

Search Constraints

Start Over You searched for: Author "Jacoby, Meagan A." Remove constraint Author: "Jacoby, Meagan A."
365 results on '"Jacoby, Meagan A."'

Search Results

51. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers

52. Daratumumab in transfusion‐dependent patients with low or intermediate‐ 1 risk myelodysplastic syndromes

53. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

55. Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia

56. Post-Marketing Observational Study to Assess the Incidence of Infusion-Related Reactions in Adult Patients with Therapy-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes Who Were Treated with CPX-351

58. Signaling Gene Mutations Are Characterized By Diverse Patterns of Expansion and Contraction during Progression from MDS to Secondary AML

59. MDS-141: The Prognostic Impact of Cytogenetic Scores in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Venetoclax and Azacitidine in a Phase 1 Study

61. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome

63. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

64. 386 - A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

66. A Study of Tbo-Filgrastim (Granix) to Disrupt the Bone Marrow Microenvironment in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

67. Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance

68. Exome analysis of treatment‐related AML after APL suggests secondary evolution

69. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy

70. Mutation Clearance after Transplantation for Myelodysplastic Syndrome

72. Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.

73. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant

74. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

75. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

76. Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant

77. Rare Pre-Existing MDS Subclones Contribute to Secondary AML Progression

78. Deleterious Germline Mutations in Telomere Maintenance Genes Identified in a Subset of Patients with Myelodysplastic Syndrome and Idiopathic Pulmonary Fibrosis

79. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

80. Exome analysis of treatment‐related AML after APL suggests secondary evolution.

81. Reduced Subclone Diversity in Clonal Cytopenia of Undetermined Significance Compared to Myelodysplastic Syndrome

82. Efficacy and Safety of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naive, Higher-Risk Myelodysplastic Syndromes

83. Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation

84. Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia

85. A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome

86. Detection of Clonal Hematopoiesis in Cytopenic Patients Using Targeted Sequencing

87. Safety, Efficacy, and Determination of the Recommended Phase 2 Dose for the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330)

88. Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients

89. Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

90. Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes

93. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

95. A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia

96. Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

97. Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

98. A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS

99. The impact of CD34+ cell dose and comorbidities on engraftment following autologous hematopoietic stem cell transplantation (ASCT).

100. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia

Catalog

Books, media, physical & digital resources